RxDoctor Payments Data

Krista Desimoni, PA

Physician Assistant · Asheville, NCNPI 1881220275

Payments from drug & device makers

$3,575in general payments, 2019–2025

Across 96 payments — averaging $37.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$510
  • Ardelyx, Inc.$225
  • Gilead$196
  • Madrigal Pharmaceuticals$185
  • Ipsen Biopharmaceuticals, Inc$159
  • plus $842 from 14 others

What the payments were for

  • Food & beverage$3,47397%
  • Education$1023%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,575 in reported general payments places this provider in the 85th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$38,490
Medicare patients
280
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib12$79,490
LinzessLinaclotide47$41,397
CreonLipase/Protease/Amylase19$36,920
MovantikNaloxegol Oxalate28$16,526
MotegrityPrucalopride Succinate18$14,008
Mesalamine12$6,274
Colesevelam Hcl18$3,084
Sucralfate19$2,183
Omeprazole157$1,992
Colestipol Hcl29$1,911
Pantoprazole Sodium96$1,293
Famotidine117$948
Balsalazide Disodium15$804
Esomeprazole Magnesium29$799
Dicyclomine Hcl29$520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess, Creon$1,459$157,80778 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$71$14,00818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →